Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.1650+0.0150 (+0.48%)
At close: 03:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.1500
Open3.1500
Bid2.9100 x 900
Ask3.8500 x 1200
Day's range3.0200 - 3.1650
52-week range1.7500 - 13.3800
Volume2,000
Avg. volume6,515
Market cap7.739M
Beta (5Y monthly)1.78
PE ratio (TTM)N/A
EPS (TTM)-18.5300
Earnings date04 Mar 2024 - 18 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for

  • GlobeNewswire

    Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

    - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G